ViaLase, Inc. is a clinical-stage medical technology company in Aliso Viejo, California building the first femtosecond laser designed to treat primary open-angle glaucoma without cutting into the eye. Its ViaLuxe Laser System pairs micron-level, high-definition imaging with a femtosecond laser to perform a noninvasive, image-guided trabeculotomy - branded FLigHT - that creates a drainage channel through the trabecular meshwork to lower intraocular pressure. Founded in 2019 by femtosecond-laser pioneer Tibor Juhasz, the company has raised more than $115 million, earned a CE Mark in Europe, and begun a U.S. IDE clinical trial.
Shawn O'Neil is the CEO of ViaLase, a clinical-stage medtech company building FLIGHT, an incision-free femtosecond laser procedure for glaucoma. He spent more than two decades at Alcon rising to head of sales and marketing for surgical glaucoma, then ran commercial at Sight Sciences before joining ViaLase as Chief Commercial Officer and stepping up to CEO in July 2025. His career has been a running tour of the products that reshaped eye surgery: EX-PRESS, LenSx, CyPass, OMNI, TearCare, and now a laser that treats glaucoma without ever touching the eye with a blade.